Questions and answers about the management of Crohn s disease and ulcerative colitis with vedolizumab.

Abstract

Vedolizumab is an anti-integrin monoclonal antibody indicated for the treatment of patients with moderately to severely active Crohn s disease and ulcerative colitis who have failed conventional or anti-TNF therapies. The objective of this article is to answer a series of very practical questions regarding the management of both diseases with vedolizumab, based on data from published literature, as well as on the experience acquired by the authors in clinical practice in recent years.